CST3 Antikörper

Produktnummer ABIN1045447

Produktdetails anti-CST3 Antikörper

Target: CST3 (Cystatin C (CST3))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CST3 Antikörper ist unkonjugiert

Applikation: ELISA, Immunohistochemistry (IHC)

Spezifität: Specific for Human Cystatin C denatured and native forms

Kreuzreaktivität: Human

Aufreinigung: Protein G purified

Immunogen: Recombinant Human Cystatin C protein

Klon: 3A1B7

Isotyp: IgG2b

Anwendungsinformationen

Applikationshinweise: Recommended dilution:IHC:1:50-1:500,

Kommentare:

Other species are not tested. Please decide the specificity by homology

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handhabung: Avoid freeze and thaw cycles.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Referenzen für anti-CST3 Antikörper (ABIN1045447)

Targońska-Stepniak, Majdan: "Cystatin C concentration is correlated with disease activity in rheumatoid arthritis patients." in: Scandinavian journal of rheumatology, Vol. 40, Issue 5, pp. 341-6, (2011) (PubMed).

López Gómez, Sacristán Enciso, Micó, Arias Meneses, de Sande Medel, Alejo: "Serum cystatin C and microalbuminuria in the detection of vascular and renal damage in early stages." in: Nefrología : publicación oficial de la Sociedad Española Nefrologia, Vol. 31, Issue 5, pp. 560-6, (2011) (PubMed).

Warwas, Piwowar: "[Urinary cystatin C as a biomarker of renal tubular injury]." in: Postȩpy higieny i medycyny doświadczalnej (Online), Vol. 65, pp. 562-8, (2011) (PubMed).

Reznichenko, Panphilova, Evdokimova, Osmolovskaia, Chumakova, Dankovtseva, Baklanova, Barinov, Sidorenko, Zateĭshchikov: "[Cystatin C level is independently related to risk of unfavorable outcome after acute coronary syndrome in individuals with normal or moderately reduced renal function]." in: Kardiologiia, Vol. 51, Issue 6, pp. 4-10, (2011) (PubMed).

Ito, Pacold, Durazo-Arvizu, Liu, Shilipak, Goff, Tracy, Kramer: "The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis." in: American journal of epidemiology, Vol. 174, Issue 8, pp. 949-57, (2011) (PubMed).

Borges, Hirota, Quinto, Ribeiro, Zanella, Batista: "Is cystatin C a useful marker in the detection of diabetic kidney disease?" in: Nephron. Clinical practice, Vol. 114, Issue 2, pp. c127-34, (2010) (PubMed).

Spanaus, Kollerits, Ritz, Hersberger, Kronenberg, von Eckardstein,: "Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease." in: Clinical chemistry, Vol. 56, Issue 5, pp. 740-9, (2010) (PubMed).

Shlipak, Katz, Kestenbaum, Fried, Newman, Siscovick, Stevens, Sarnak: "Rate of kidney function decline in older adults: a comparison using creatinine and cystatin C." in: American journal of nephrology, Vol. 30, Issue 3, pp. 171-8, (2009) (PubMed).

Muntner, Vupputuri, Coresh, Uribarri, Fox: "Metabolic abnormalities are present in adults with elevated serum cystatin C." in: Kidney international, Vol. 76, Issue 1, pp. 81-8, (2009) (PubMed).

Hojs, Bevc, Ekart, Gorenjak, Puklavec: "Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease." in: Clinical nephrology, Vol. 70, Issue 1, pp. 10-7, (2008) (PubMed).

Delanaye, Cavalier, Radermecker, Paquot, Depas, Chapelle, Scheen, Krzesinski: "Cystatin C or creatinine for detection of stage 3 chronic kidney disease in anorexia nervosa." in: Nephron. Clinical practice, Vol. 110, Issue 3, pp. c158-63, (2008) (PubMed).

Yang, Peng, Lin, Wang, Huang: "Use of serum cystatin C to detect early decline of glomerular filtration rate in type 2 diabetes." in: Internal medicine (Tokyo, Japan), Vol. 46, Issue 12, pp. 801-6, (2007) (PubMed).

Pucci, Triscornia, Lucchesi, Fotino, Pellegrini, Pardini, Miccoli, Del Prato, Penno: "Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients." in: Clinical chemistry, Vol. 53, Issue 3, pp. 480-8, (2007) (PubMed).

Hojs, Bevc, Ekart, Gorenjak, Puklavec: "Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function." in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 21, Issue 7, pp. 1855-62, (2006) (PubMed).

Shlipak, Katz, Sarnak, Fried, Newman, Stehman-Breen, Seliger, Kestenbaum, Psaty, Tracy, Siscovick: "Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease." in: Annals of internal medicine, Vol. 145, Issue 4, pp. 237-46, (2006) (PubMed).

Mussap, Dalla Vestra, Fioretto, Saller, Varagnolo, Nosadini, Plebani: "Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients." in: Kidney international, Vol. 61, Issue 4, pp. 1453-61, (2002) (PubMed).

Basile, Drüeke, Lacour, Ulmann, Bourdeau, Utzinger, Dubost: "Total parathyroidectomy and delayed parathyroid autotransplantation using a simplified cryopreservation technique: human and animal studies." in: American journal of kidney diseases : the official journal of the National Kidney Foundation, Vol. 3, Issue 5, pp. 366-70, (1984) (PubMed).

Details zu CST3

Target: CST3 (Cystatin C (CST3))

Andere Bezeichnung: CST3 (CST3 Produkte)

Synonyme: armd11 antikoerper, fb51d07 antikoerper, wu:fb24g06 antikoerper, wu:fb51d07 antikoerper, wu:fc55f03 antikoerper, zgc:136227 antikoerper, ARMD11 antikoerper, CysC antikoerper, CYSC antikoerper, cystatin C antikoerper, cystatin C L homeolog antikoerper, cystatin C (amyloid angiopathy and cerebral hemorrhage) antikoerper, cystatin 3 antikoerper, CST3 antikoerper, cst3.L antikoerper, cst3 antikoerper, cystatin 3 antikoerper, Cst3 antikoerper

Hintergrund:

Background: Defects in CST3 are the cause of amyloidosis type 6 (AMYL6) [MIM:105150], also known as hereditary cerebral hemorrhage with amyloidosis (HCHWA), cerebral amyloid angiopathy (CAA) or cerebroarterial amyloidosis Icelandic type. AMYL6 is a hereditary generalized amyloidosis due to cystatin C amyloid deposition. Cystatin C amyloid accumulates in the walls of arteries, arterioles, and sometimes capillaries and veins of the brain, and in various organs including lymphoid tissue, spleen, salivary glands, and seminal vesicles. Amyloid deposition in the cerebral vessels results in cerebral amyloid angiopathy, cerebral hemorrhage and premature stroke. Cystatin C levels in the cerebrospinal fluid are abnormally low.Genetic variations in CST3 are associated with age-related macular degeneration type 11 (ARMD11) [MIM:611953]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

Aliases: CysC,Cystatin-3,Gamma-trace,Neuroendocrine basic polypeptide,Post-gamma-globulin

UniProt: P01034